<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082914</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000361715</org_study_id>
    <secondary_id>NCI-04-C-0134</secondary_id>
    <nct_id>NCT00082914</nct_id>
    <nct_alias>NCT00078702</nct_alias>
  </id_info>
  <brief_title>Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer</brief_title>
  <official_title>Phase II Evaluation of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating&#xD;
      patients with metastatic melanoma or metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical response in patients with metastatic melanoma or metastatic&#xD;
           kidney cancer treated with denileukin diftitox.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether changes occur in levels of CD4-positive CD25-positive lymphocytes in&#xD;
           the peripheral blood of these patients before and after treatment with this drug.&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease type (metastatic melanoma vs metastatic&#xD;
      kidney cancer).&#xD;
&#xD;
      Patients receive denileukin diftitox IV over 1 hour on days 1-5, 21-25, 42-46, and 63-67.&#xD;
      Treatment repeats every 84 days (12 weeks) for up to a maximum total of 5 courses in the&#xD;
      absence of disease progression, autoimmune ocular toxicity attributable to denileukin&#xD;
      diftitox, or any other unacceptable toxicity. At any time during therapy, patients achieving&#xD;
      a complete response receive 1 additional course of therapy after the complete response.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-96 patients (5-48 per stratum) will be accrued for this&#xD;
      study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of CD4-positive CD25-positive lymphocytes in the peripheral blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Melanoma&#xD;
&#xD;
               -  Kidney cancer&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Documented disease progression while receiving standard therapy&#xD;
&#xD;
          -  No resectable local or regional disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 90,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count ≥ 500/mm^3&#xD;
&#xD;
          -  No concurrent coagulation disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (&lt; 3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  AST and ALT &lt; 3 times normal&#xD;
&#xD;
          -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Normal thallium stress test*&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No history of severe coronary artery disease&#xD;
&#xD;
          -  No major medical illness of the cardiovascular system NOTE: *For patients &gt; 50 years&#xD;
             of age OR who have a history of cardiovascular disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major medical illness of the respiratory system&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No presence of opportunistic infections&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No other known immunodeficiency&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No sensitivity to denileukin diftitox or any of its components (e.g., diphtheria&#xD;
             toxin, interleukin-2, or excipients)&#xD;
&#xD;
          -  Willing to undergo leukapheresis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior treatment with interleukin-2 allowed provided the patient's disease status&#xD;
             required this therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior systemic anticancer therapy&#xD;
&#xD;
          -  No other concurrent systemic anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2004</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

